IL6R
Interleukin-6 receptor subunit alpha
As of the edition of 20 October 2026, IL6R (interleukin-6 receptor subunit alpha, UniProt P08887) has 5 drugs tested at it and 4 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08887
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 10
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Cancer; Lungs and airways; Blood and lymph; Infections; Heart and blood vessels
- Registered trials of its drugs
- 528
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 1 |
| Went quiet | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tocilizumab | Marketed | Phase 4 | Ends 2028 |
| Sarilumab | Marketed | Phase 4 | Ends 2029 |
| Satralizumab | Marketed | Phase 4 | Ends 2032 |
| Vobarilizumab | Went quiet | Phase 2 | none listed |
| Levilimab | Active | Phase 3 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 3 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Sanofi | Route B |
The other 3 companies at IL6R
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at IL6R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.